Manias Karen A, Gill Simrandip K, MacPherson Lesley, Oates Adam, Pinkey Benjamin, Davies Paul, Zarinabad Niloufar, Davies Nigel P, Babourina-Brooks Ben, Wilson Martin, Peet Andrew C
Institute of Cancer and Genomic Sciences, University of Birmingham, UK.
Department of Pediatric Oncology, Birmingham Children's Hospital, UK.
Neurooncol Pract. 2019 Dec;6(6):428-437. doi: 10.1093/nop/npz010. Epub 2019 May 9.
H-magnetic resonance spectroscopy (MRS) facilitates noninvasive diagnosis of pediatric brain tumors by providing metabolite profiles. Prospective studies of diagnostic accuracy and comparisons with conventional MRI are lacking. We aimed to evaluate diagnostic accuracy of MRS for childhood brain tumors and determine added clinical value compared with conventional MRI.
Children presenting to a tertiary pediatric center with brain lesions from December 2015 through 2017 were included. MRI and single-voxel MRS were acquired on 52 tumors and sequentially interpreted by 3 radiologists, blinded to histopathology. Proportions of correct diagnoses and interrater agreement at each stage were compared. Cases were reviewed to determine added value of qualitative radiological review of MRS through increased certainty of correct diagnosis, reduced number of differentials, or diagnosis following spectroscopist evaluation. Final diagnosis was agreed by the tumor board at study end.
Radiologists' principal MRI diagnosis was correct in 69%, increasing to 77% with MRS. MRI + MRS resulted in significantly more additional correct diagnoses than MRI alone ( = .035). There was a significant increase in interrater agreement when correct with MRS ( = .046). Added value following radiologist interpretation of MRS occurred in 73% of cases, increasing to 83% with additional spectroscopist review. First histopathological diagnosis was available a median of 9.5 days following imaging, with 25% of all patients managed without conclusive histopathology.
MRS can improve the accuracy of noninvasive diagnosis of pediatric brain tumors and add value in the diagnostic pathway. Incorporation into practice has the potential to facilitate early diagnosis, guide treatment planning, and improve patient care.
氢磁共振波谱(MRS)通过提供代谢物谱有助于小儿脑肿瘤的无创诊断。目前缺乏关于诊断准确性的前瞻性研究以及与传统MRI的比较。我们旨在评估MRS对儿童脑肿瘤的诊断准确性,并确定与传统MRI相比其额外的临床价值。
纳入2015年12月至2017年期间在一家三级儿科中心因脑病变就诊的儿童。对52个肿瘤进行了MRI和单体素MRS检查,并由3名放射科医生进行顺序解读,他们对组织病理学结果不知情。比较每个阶段正确诊断的比例和评估者间的一致性。回顾病例以确定通过提高正确诊断的确定性、减少鉴别诊断数量或在光谱学家评估后进行诊断,MRS的定性放射学评估的附加价值。最终诊断在研究结束时由肿瘤委员会确定。
放射科医生对MRI的主要诊断正确率为69%,MRS检查后提高到77%。MRI + MRS比单独的MRI产生了显著更多的额外正确诊断(P = 0.035)。当MRS诊断正确时,评估者间的一致性有显著提高(P = 0.046)。放射科医生对MRS解读后的附加价值在73%的病例中出现,在光谱学家的额外评估后增加到83%。首次组织病理学诊断在成像后中位9.5天获得,25%的所有患者在没有明确组织病理学结果的情况下接受治疗。
MRS可以提高小儿脑肿瘤无创诊断的准确性,并在诊断过程中增加价值。将其纳入实践有可能促进早期诊断、指导治疗计划并改善患者护理。